https://doi.org/10.1016/S2213-2600(24)00264-9

IF 38.7 1区医学 Q1 CRITICAL CARE MEDICINE Lancet Respiratory Medicine Pub Date : 2024-11-22 DOI:10.1016/s2213-2600(24)00370-9

{"title":"https://doi.org/10.1016/S2213-2600(24)00264-9","authors":"","doi":"10.1016/s2213-2600(24)00370-9","DOIUrl":null,"url":null,"abstract":"Léna H, Greiller L, Cropet C, et al. Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08–2015 ENERGY): a randomised, open-label, phase 3 study. Lancet Respir Med 2024; published online Oct 29. https://doi.org/10.1016/S2213-2600(24)00264-9—In figure 3B of this Article, the y-axis title should have read “Overall survival (%)”. This correction has been made to the online version as of Nov 22, 2024, and will be made to the printed version.","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"59 1","pages":""},"PeriodicalIF":38.7000,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Correction to Lancet Respir Med 2024; published online Oct 29. https://doi.org/10.1016/S2213-2600(24)00264-9\",\"authors\":\"\",\"doi\":\"10.1016/s2213-2600(24)00370-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Léna H, Greiller L, Cropet C, et al. Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08–2015 ENERGY): a randomised, open-label, phase 3 study. Lancet Respir Med 2024; published online Oct 29. https://doi.org/10.1016/S2213-2600(24)00264-9—In figure 3B of this Article, the y-axis title should have read “Overall survival (%)”. This correction has been made to the online version as of Nov 22, 2024, and will be made to the printed version.\",\"PeriodicalId\":51307,\"journal\":{\"name\":\"Lancet Respiratory Medicine\",\"volume\":\"59 1\",\"pages\":\"\"},\"PeriodicalIF\":38.7000,\"publicationDate\":\"2024-11-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lancet Respiratory Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/s2213-2600(24)00370-9\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CRITICAL CARE MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Respiratory Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/s2213-2600(24)00370-9","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}

引用次数: 0

摘要

Léna H, Greiller L, Cropet C, et al. Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study.https://doi.org/10.1016/S2213-2600(24)00264-9-In figure 3B of this Article, the y-axis title should have read "Overall survival (%)".截至 2024 年 11 月 22 日，在线版本已作此更正，印刷版本也将进行更正。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Correction to Lancet Respir Med 2024; published online Oct 29. https://doi.org/10.1016/S2213-2600(24)00264-9

Léna H, Greiller L, Cropet C, et al. Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08–2015 ENERGY): a randomised, open-label, phase 3 study. Lancet Respir Med 2024; published online Oct 29. https://doi.org/10.1016/S2213-2600(24)00264-9—In figure 3B of this Article, the y-axis title should have read “Overall survival (%)”. This correction has been made to the online version as of Nov 22, 2024, and will be made to the printed version.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Lancet Respiratory Medicine RESPIRATORY SYSTEM-RESPIRATORY SYSTEM

CiteScore

87.10

自引率

0.70%

发文量

572

期刊介绍： The Lancet Respiratory Medicine is a renowned journal specializing in respiratory medicine and critical care. Our publication features original research that aims to advocate for change or shed light on clinical practices in the field. Additionally, we provide informative reviews on various topics related to respiratory medicine and critical care, ensuring a comprehensive coverage of the subject. The journal covers a wide range of topics including but not limited to asthma, acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), tobacco control, intensive care medicine, lung cancer, cystic fibrosis, pneumonia, sarcoidosis, sepsis, mesothelioma, sleep medicine, thoracic and reconstructive surgery, tuberculosis, palliative medicine, influenza, pulmonary hypertension, pulmonary vascular disease, and respiratory infections. By encompassing such a broad spectrum of subjects, we strive to address the diverse needs and interests of our readership.